Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Volume to dissolve applied dose (VDAD) and apparent dissolution rate (ADR): tools to predict in vivo bioavailability from orally applied drug suspensions.
Muenster U, Pelzetter C, Backensfeld T, Ohm A, Kuhlmann T, Mueller H, Lustig K, Keldenich J, Greschat S, Göller AH, Gnoth MJ. Muenster U, et al. Among authors: lustig k. Eur J Pharm Biopharm. 2011 Aug;78(3):522-30. doi: 10.1016/j.ejpb.2011.01.023. Epub 2011 Feb 16. Eur J Pharm Biopharm. 2011. PMID: 21315152
Biphenyls as potent vitronectin receptor antagonists. Part 3: Squaric acid amides.
Urbahns K, Härter M, Albers M, Schmidt D, Stelte-Ludwig B, Brüggemeier U, Vaupel A, Keldenich J, Lustig K, Tsujishita H, Gerdes C. Urbahns K, et al. Among authors: lustig k. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6151-4. doi: 10.1016/j.bmcl.2007.09.039. Epub 2007 Sep 14. Bioorg Med Chem Lett. 2007. PMID: 17910915
Prediction of a potentially effective dose in humans for BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein (CETP) by allometric species scaling and combined pharmacodynamic and physiologically-based pharmacokinetic modelling.
Weber O, Willmann S, Bischoff H, Li V, Vakalopoulos A, Lustig K, Hafner FT, Heinig R, Schmeck C, Buehner K. Weber O, et al. Among authors: lustig k. Br J Clin Pharmacol. 2012 Feb;73(2):219-31. doi: 10.1111/j.1365-2125.2011.04064.x. Br J Clin Pharmacol. 2012. PMID: 21762205 Free PMC article.
Glycine amides as PPARalpha agonists.
Urbahns K, Woltering M, Nikolic S, Pernerstorfer J, Bischoff H, Dittrich-Wengenroth E, Lustig K. Urbahns K, et al. Among authors: lustig k. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3376-9. doi: 10.1016/j.bmcl.2010.04.019. Epub 2010 Apr 13. Bioorg Med Chem Lett. 2010. PMID: 20452212
Chromanol derivatives--a novel class of CETP inhibitors.
Vakalopoulos A, Schmeck C, Thutewohl M, Li V, Bischoff H, Lustig K, Weber O, Paulsen H, Elias H. Vakalopoulos A, et al. Among authors: lustig k. Bioorg Med Chem Lett. 2011 Jan 1;21(1):488-91. doi: 10.1016/j.bmcl.2010.10.110. Epub 2010 Oct 26. Bioorg Med Chem Lett. 2011. PMID: 21084191
Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure.
Follmann M, Ackerstaff J, Redlich G, Wunder F, Lang D, Kern A, Fey P, Griebenow N, Kroh W, Becker-Pelster EM, Kretschmer A, Geiss V, Li V, Straub A, Mittendorf J, Jautelat R, Schirok H, Schlemmer KH, Lustig K, Gerisch M, Knorr A, Tinel H, Mondritzki T, Trübel H, Sandner P, Stasch JP. Follmann M, et al. Among authors: lustig k. J Med Chem. 2017 Jun 22;60(12):5146-5161. doi: 10.1021/acs.jmedchem.7b00449. Epub 2017 Jun 12. J Med Chem. 2017. PMID: 28557445 Free article.
Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 85-8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases.
von Nussbaum F, Li VM, Allerheiligen S, Anlauf S, Bärfacker L, Bechem M, Delbeck M, Fitzgerald MF, Gerisch M, Gielen-Haertwig H, Haning H, Karthaus D, Lang D, Lustig K, Meibom D, Mittendorf J, Rosentreter U, Schäfer M, Schäfer S, Schamberger J, Telan LA, Tersteegen A. von Nussbaum F, et al. Among authors: lustig k. ChemMedChem. 2015 Jul;10(7):1163-73. doi: 10.1002/cmdc.201500131. Epub 2015 Jun 17. ChemMedChem. 2015. PMID: 26083237 Free PMC article.
64 results